Amgen - In the News - Prolia� in the News

print
mail

In the News

Prolia® (denosumab) in the News


Sep. 20, 2012	Press Release: FDA Approves New Indication For Prolia® (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture
Sep. 20, 2012	Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)
Sep. 20, 2012	Amgen Modifies Prolia® Risk Evaluation and Mitigation Strategy (REMS) Materials (US)
Jun. 7, 2012	Amgen Modifies Prolia® Risk Evaluation and Mitigation Strategy (REMS) Materials (US)
May 11, 2012	Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)
Sep. 19, 2011	Press Release: FDA Approves New Indications for Prolia® (denosumab) for the Treatment of Bone Loss in Patients with Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Sep. 19, 2011	Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)
Sep. 19, 2011	Amgen Modifies Prolia® Risk Evaluation and Mitigation Strategy (REMS) Materials (US)
Jul. 22, 2011	Amgen Modifies U.S. Prescribing Information for Prolia® (denosumab)
Aug. 6, 2010	Prolia� (denosumab) Receives Approval in Switzerland and Canada
Jun. 8, 2010	Amgen Issues Statement About Prolia® (denosumab) Approval in Australia
Jun. 1, 2010	Press Release: FDA Approves Amgen's Prolia� (denosumab) for Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Jun. 1, 2010	Prolia� Prescribing Information (US)
Jun. 1, 2010	Prolia� Risk Evaluation and Mitigation Strategy (REMS) Materials (US)
May 28, 2010	Press Release: Prolia® (denosumab) Granted Marketing Authorization in the European Union
May 28, 2010	Prolia® (denosumab) Summary of Medicinal Product Characteristics (EU)

Background Documents

Prescribing information for Prolia�

footer